Physician profile
Glennetta Coleman
NPI 1063449296
$6,932.54
in general payments reported to CMS, 2019-2025
28 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,579 · 2020: $1,418 · 2021: $1,255 · 2022: $1,167 · 2023: $606 · 2024: $548 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $941.20 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $891.48 | 2019-2024 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals Lp | $840.99 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $594.70 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $549.79 | 2019-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $547.04 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $427.82 | 2019-2025 | Jardiance |
| Pfizer INC. | $333.66 | 2019-2022 | |
| Glaxosmithkline, LLC. | $322.74 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $297.63 | 2019-2023 | Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.94 | 2019-2023 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $161.52 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $121.05 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.03 | 2019-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $101.80 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $94.75 | 2021-2023 | Freestyle Libre 3 |
| Abbvie INC. | $56.41 | 2021-2024 | |
| Mylan Specialty L.P. | $44.43 | 2020-2021 | |
| Exact Sciences Corporation | $44.43 | 2024-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $37.10 | 2020-2021 | |
| Genentech USA, INC. | $24.91 | 2021 | |
| Horizon Therapeutics Plc | $23.09 | 2019-2020 | |
| Dexcom, INC. | $19.85 | 2024 | Dexcom G6 Transmitter |
| Ironwood Pharmaceuticals, INC | $16.89 | 2019 | |
| Boston Scientific Corporation | $15.95 | 2022 | |
| Ibsa Pharma INC. | $15.62 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.97 | 2022 | |
| Allergan, INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glennetta Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.